PPCB — Propanc Biopharma Cashflow Statement
0.000.00%
- $20.23m
- $21.89m
Annual cashflow statement for Propanc Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.03 | -2.66 | -2.66 | -1.82 | -58.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.44 | 1.05 | 1.08 | 0.468 | 57.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.443 | 0.167 | 0.473 | 0.417 | 1.14 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -1.15 | -1.44 | -1.11 | -0.935 | -0.405 |
| Financing Cash Flow Items | 0 | — | — | — | -0.265 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.06 | 1.49 | 1.11 | 0.942 | 0.491 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.065 | 0.002 | 0.006 | 0.011 | -0.009 |